Showing 2911-2920 of 4107 results for "".
- NRS Launches Updated Version of "Understanding Rosacea" for Patientshttps://practicaldermatology.com/news/nrs-launches-updated-version-of-understanding-rosacea-for-patients/2460721/The National Rosacea Society has updated its most popular educational booklet. The new edition of “Understanding Rosacea” incorporates the updated standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwid
- Study: Clear Masks Improve Communication with Patientshttps://practicaldermatology.com/news/study-clear-masks-improve-communication-with-patients/2460716/Seeing really is believing. New research shows that doctors who wear transparent face masks greatly improve communication with patients compared to doctors whose faces are blocked by a standard face masks. What’s more, providers who wore the ClearMask are also perc
- Dr. Roy Geronemus Named CEO of NavaDermhttps://practicaldermatology.com/news/dr-roy-geronemus-named-ceo-of-navaderm/2460715/New York City dermatologist Roy Geronemus, MD is NavaDerm Partners’ new Chief Executive Officer. Dr. Geronemus graduated from Harvard University and pursued his medical education at the University of Miami School of Medicine where he is a member of the school's Alumni Hal
- With Pfizer Grant, GW Dermatology to Expand Telederm for Eczemahttps://practicaldermatology.com/news/with-pfizer-grant-gw-dermatology-to-expand-telederm-for-eczema/2460714/The George Washington University (GW) Department of Dermatology will use a $250,000 grant from Pfizer to expand accessible teledermatology for atopic dermatitis patients in Washington, DC. The dermatology team at GW, led by
- New from Solta: Meet the Next Generation Clear + Brilliant Laserhttps://practicaldermatology.com/news/new-from-solta-meet-the-next-generation-clear-brilliant-laser/2460711/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a
- New Research Highlights Global Challenge of Leprosyhttps://practicaldermatology.com/news/new-research-highlights-global-challenge-of-leprosy/2460706/The global problem of leprosy may be bigger than recognized, new research suggests. In fact, 40 million individuals around the world require preventive treatment in order to reduce the incidence of leprosy or Hansen’s Disease by 90% in 22 years. The new research by
- Robert Moccia Takes the Helm at STRATA Skin Scienceshttps://practicaldermatology.com/news/robert-moccia-takes-the-helm-at-strata-skin-sciences/2460705/Robert (Bob) Moccia is the new President and Chief Executive Officer and a member of the board of STRATA Skin Sciences, Inc. He replaces Dolev Rafaeli, PhD, who stepped down last month. “I am confident that STRATA has the technology
- Project IMPACT from VisualDX Aims to Reduce Disparities in Medicinehttps://practicaldermatology.com/news/project-impact-from-visualdx-aims-reduce-disparities-in-medicine/2460704/VisualDX is launching Project IMPACT (Improving Medicine’s Power to Address Care and Treatment), a global effort to reduce disparities in medicine and highlight ways to bridge gaps of knowledge and improve healthcare outcomes for patients of color. Inaugural members include thought leaders
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident
- With sNDA, Amgen Seeks Approval for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/with-snda-amgen-seeks-approval-for-otezla-in-mild-to-moderate-pso/2460700/Amgen has submitted a supplemental New Drug Application (sNDA) to the FDA for Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The sNDA is based on data from the Phase 3 ADVANCE trial tha